Fulcrum Therapeutics, Inc.
FULC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001680581
In the last 90 days, Fulcrum Therapeutics, Inc. insiders filed 2 open-market purchases and 0 sales; 154 institutions reported holding it in 13F filings for Q2 2026, worth $291.3M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Fulcrum Therapeutics, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 81 | 101 | +20 |
| Shares | 56.4M | 61.1M | +4.69M (+8.3%) |
| Value | $250.4M | $412.3M | +$161.9M (+64.7%) |
New holders (31)
Institutions that held Fulcrum Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
Sold out (11)
Institutions that held Fulcrum Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Vivo Capital, LLC | 520,000 | $2.31M |
| Hudson Bay Capital Management LP | 196,488 | $872.4K |
| Jump Financial, LLC | 91,790 | $407.5K |
| Occudo Quantitative Strategies LP | 87,372 | $387.9K |
| Squarepoint Ops LLC | 58,900 | $261.5K |
| Renaissance Technologies LLC | 52,734 | $234.0K |
| XTX Topco Ltd | 38,918 | $172.8K |
| Simplex Trading, LLC | 25,424 | $112.0K |
| Verition Fund Management LLC | 19,212 | $85.3K |
| Graham Capital Management, L.P. | 11,845 | $52.6K |
| Centiva Capital, LP | 10,747 | $47.7K |